Jason Bednar
Stock Analyst at Piper Sandler
(2.20)
# 2,685
Out of 4,732 analysts
151
Total ratings
45.08%
Success rate
n/a
Average return
Main Sectors:
Stocks Rated by Jason Bednar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Maintains: Overweight | $180 → $210 | $172.29 | +21.89% | 13 | Dec 18, 2024 | |
| NVCR NovoCure | Maintains: Overweight | $28 → $42 | $26.17 | +60.49% | 9 | Dec 13, 2024 | |
| PDCO Patterson Companies | Maintains: Neutral | $26 → $24 | $30.90 | -22.33% | 9 | Dec 6, 2024 | |
| KRMD KORU Medical Systems | Maintains: Overweight | $3 → $3.5 | $4.09 | -14.43% | 5 | Nov 14, 2024 | |
| SOLV Solventum | Maintains: Neutral | $71 → $75 | $73.51 | +2.03% | 2 | Nov 8, 2024 | |
| MDXH MDxHealth | Maintains: Overweight | $8 → $6 | $1.96 | +206.12% | 5 | Nov 7, 2024 | |
| NVST Envista Holdings | Maintains: Neutral | $16 → $17 | $19.83 | -14.27% | 10 | Oct 31, 2024 | |
| ALGN Align Technology | Maintains: Overweight | $285 → $275 | $224.23 | +22.64% | 27 | Oct 24, 2024 | |
| STE STERIS | Upgrades: Overweight | $230 → $260 | $209.62 | +24.03% | 8 | Oct 24, 2024 | |
| MMSI Merit Medical Systems | Reiterates: Overweight | $100 → $110 | $102.90 | +6.90% | 7 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $115 → $120 | $93.27 | +28.66% | 11 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 | $3.91 | +79.03% | 5 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3.5 → $1 | $0.42 | +139.52% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $6.26 | +91.69% | 10 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 | $73.22 | +17.45% | 6 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $13 | $12.98 | +0.15% | 1 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $35 → $32 | $18.77 | +70.48% | 7 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $372 | $592.64 | -37.23% | 4 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.17 | +314.75% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $305 → $280 | $237.38 | +17.95% | 6 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $95 | $84.74 | +12.11% | 1 | Apr 19, 2023 |
Masimo
Dec 18, 2024
Maintains: Overweight
Price Target: $180 → $210
Current: $172.29
Upside: +21.89%
NovoCure
Dec 13, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $26.17
Upside: +60.49%
Patterson Companies
Dec 6, 2024
Maintains: Neutral
Price Target: $26 → $24
Current: $30.90
Upside: -22.33%
KORU Medical Systems
Nov 14, 2024
Maintains: Overweight
Price Target: $3 → $3.5
Current: $4.09
Upside: -14.43%
Solventum
Nov 8, 2024
Maintains: Neutral
Price Target: $71 → $75
Current: $73.51
Upside: +2.03%
MDxHealth
Nov 7, 2024
Maintains: Overweight
Price Target: $8 → $6
Current: $1.96
Upside: +206.12%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $16 → $17
Current: $19.83
Upside: -14.27%
Align Technology
Oct 24, 2024
Maintains: Overweight
Price Target: $285 → $275
Current: $224.23
Upside: +22.64%
STERIS
Oct 24, 2024
Upgrades: Overweight
Price Target: $230 → $260
Current: $209.62
Upside: +24.03%
Merit Medical Systems
Sep 9, 2024
Reiterates: Overweight
Price Target: $100 → $110
Current: $102.90
Upside: +6.90%
Aug 29, 2024
Reiterates: Overweight
Price Target: $115 → $120
Current: $93.27
Upside: +28.66%
Aug 15, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.91
Upside: +79.03%
Aug 7, 2024
Maintains: Overweight
Price Target: $3.5 → $1
Current: $0.42
Upside: +139.52%
Aug 1, 2024
Maintains: Overweight
Price Target: $14 → $12
Current: $6.26
Upside: +91.69%
Jun 21, 2024
Reiterates: Overweight
Price Target: $86
Current: $73.22
Upside: +17.45%
May 21, 2024
Initiates: Neutral
Price Target: $13
Current: $12.98
Upside: +0.15%
May 3, 2024
Reiterates: Neutral
Price Target: $35 → $32
Current: $18.77
Upside: +70.48%
Jan 3, 2024
Maintains: Outperform
Price Target: $310 → $372
Current: $592.64
Upside: -37.23%
Nov 10, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.17
Upside: +314.75%
Nov 10, 2023
Maintains: Overweight
Price Target: $305 → $280
Current: $237.38
Upside: +17.95%
Apr 19, 2023
Initiates: Overweight
Price Target: $95
Current: $84.74
Upside: +12.11%